Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

MPN Advances Day 2019 | Ropeginterferon alfa-2b for polycythemia vera: impacts and considerations

Jean-Jacques Kiladjian • 15 Nov 2019
MPN Advances Day 2019
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Ropeginterferon alfa-2b

From the Myeloproliferative Neoplasms Advances Day 2019 in London, UK, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital, University of Paris, Paris, France, discusses the impacts of ropeginterferon alfa-2b treatment for polycythemia vera (PV). He also highlights the consideration that this treatment is not suitable for everyone.

More from Jean-Jacques Kiladjian

12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
2:25
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
Jean-Jacques Kiladjian • 8 Dec 2025
Preliminary results from trials targeting mutant CALR for the treatment of MPNs
1:16
Preliminary results from trials targeting mutant CALR for the treatment of MPNs
Jean-Jacques Kiladjian • 13 Jun 2025
The disease-modifying potential of CALR-targeted therapies in MPNs
0:55
The disease-modifying potential of CALR-targeted therapies in MPNs
Jean-Jacques Kiladjian • 13 Jun 2025
The management of MPNs in young patients: transitioning from pediatric to adult care
1:57
The management of MPNs in young patients: transitioning from pediatric to adult care
Jean-Jacques Kiladjian • 13 Jun 2025

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Jean-Jacques Kiladjian • 7 Dec 2025
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Jean-Jacques Kiladjian • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Jean-Jacques Kiladjian • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Jean-Jacques Kiladjian • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals